the complete guide to fda-approved peptides
from oral tablets to subcutaneous implants, here's every fda-approved peptide therapeutic, what it actually treats, and what's still stuck in the research pipeline.
for educational purposes only. this article covers regulatory status and clinical data for peptide therapeutics. it does not constitute medical advice. consult a qualified healthcare professional before using any peptides.
the peptide approval gap
most peptides discussed in online communities aren't fda-approved. out of the hundreds of peptide sequences that biohackers, bodybuilders, and longevity enthusiasts talk about, only a fraction have completed the rigorous clinical trial process required for fda approval. the disconnect between what's popular and what's approved creates real confusion.
as of 2026, over 80 peptide-based drugs have received fda approval [1]. but the peptides dominating reddit threads and telegram groups -- BPC-157, TB-500, ipamorelin, CJC-1295 -- aren't among them. they exist in a regulatory gray area: legally compoundable (sometimes), widely used (definitely), but never subjected to the phase 1-2-3 trial pipeline that semaglutide or tirzepatide completed.
understanding which peptides are actually approved, which are in the pipeline, and which are strictly research compounds isn't just academic. it determines what a physician can prescribe, what insurance might cover, and what legal protections exist if something goes wrong.
fda-approved peptide therapeutics
the following peptide drugs have completed the full fda approval process. each one has phase 3 clinical trial data, a defined safety profile, and at least one approved indication. they represent the gold standard of what peptide medicine looks like when it goes through the system.
semaglutide
the most commercially successful peptide drug in history. Ozempic (subcutaneous injection, type 2 diabetes, 2017), Rybelsus (oral tablet, type 2 diabetes, 2019 -- the first oral GLP-1 receptor agonist), Wegovy (subcutaneous injection, weight management, 2021), and oral Wegovy (25 mg tablet, weight management, dec 2025 -- the first oral GLP-1 for obesity). the STEP 1 trial showed 14.9% mean weight loss at 68 weeks [2]. the oral 25 mg version achieved 16.6% at 64 weeks in the OASIS 4 trial, with one-third of participants reaching 20%+ [3].
tirzepatide
dual GIP/GLP-1 receptor agonist. Mounjaro (type 2 diabetes, may 2022), Zepbound (weight management, nov 2023), and a dec 2024 approval for obstructive sleep apnea -- the first medication ever approved for OSA [4]. the SURMOUNT-5 head-to-head trial showed 20.2% weight loss vs 13.7% for semaglutide at 72 weeks [5].
afamelanotide (Scenesse)
subcutaneous implant approved oct 2019 for erythropoietic protoporphyria (EPP). this is what the peptide community knows as melanotan I. the implant is bioabsorbable PLGA polymer, dosed every ~2 months. critical distinction: it is not approved for tanning.
setmelanotide (Imcivree)
MC4R agonist. daily subcutaneous injection approved 2020 for rare genetic obesity (POMC, PCSK1, LEPR deficiency), expanded to bardet-biedl syndrome in 2022 and children ages 2-5 in 2024.
trofinetide (Daybue)
oral solution approved march 2023 for rett syndrome. first and only drug for this condition. synthetic analog of the N-terminal tripeptide of IGF-1.
palopegteriparatide (Yorvipath)
subcutaneous injection approved august 2024 for hypoparathyroidism. first and only fda-approved treatment. prodrug of PTH(1-34).
elamipretide
subcutaneous injection, accelerated approval sept 2025 for barth syndrome. first mitochondria-targeted therapeutic. binds cardiolipin on the inner mitochondrial membrane.
bremelanotide (Vyleesi)
subcutaneous injection approved 2019 for hypoactive sexual desire disorder in premenopausal women.
tesamorelin (Egrifta)
subcutaneous injection approved 2010 for HIV-associated lipodystrophy. growth hormone-releasing hormone analog.
how peptides get into your body
the administration route determines bioavailability, convenience, and which patients can actually use a drug. peptides are large, fragile molecules, and getting them into the bloodstream intact is one of the central challenges of peptide pharmacology.
subcutaneous injection
accounts for roughly 65% of approved peptide drugs. it's the default because peptides are large molecules that get destroyed in the gut. absorption is reliable, bioavailability is high, and auto-injector pens have made the process almost trivial for patients. semaglutide, tirzepatide, setmelanotide, bremelanotide, tesamorelin, palopegteriparatide, and elamipretide all use this route.
oral delivery
was considered impossible for peptides until Novo Nordisk cracked it with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) technology. SNAC creates a local pH buffer in the stomach that protects semaglutide from enzymatic degradation and enhances absorption across the gastric epithelium. even so, oral bioavailability is only about 1% -- which is why oral Wegovy requires a 25 mg dose to match the effect of a 2.4 mg injection [6]. trofinetide (Daybue) is also administered orally as a solution.
subcutaneous implants
provide weeks-to-months of sustained release. afamelanotide's PLGA implant dissolves over ~60 days. goserelin (Zoladex) uses the same concept for prostate cancer. histrelin (Supprelin LA) lasts a full 12 months. the tradeoff: a minor surgical procedure for insertion.
nasal spray
bypasses first-pass liver metabolism and delivers peptides directly to the bloodstream through the nasal mucosa. desmopressin for diabetes insipidus and calcitonin for osteoporosis use this route. selank and semax are administered nasally in russia, though neither has fda approval [7].
emerging delivery technologies
lipid nanoparticles, transdermal microneedle patches, and hydrogel depots are all in active development. none have produced an fda-approved peptide product yet, but oral non-peptide GLP-1 agonists (like orforglipron, currently in phase 3) may change the landscape entirely by sidestepping the bioavailability problem altogether.
the pipeline -- what's coming next
three candidates are generating the most clinical excitement right now. each one addresses a different unmet need, and all three could reshape their respective therapeutic areas.
retatrutide
Eli Lilly's triple agonist (GIP + GLP-1 + glucagon receptors). phase 2 data showed up to 24.2% weight loss at 48 weeks [8]. phase 3 TRIUMPH-4 data released in 2026 showed 28.7% mean weight loss at 68 weeks -- the highest phase 3 figure for any obesity drug ever tested. seven more phase 3 readouts expected in 2026. earliest realistic fda approval: 2027-2028.
cagrisema
Novo Nordisk's fixed-dose combination of cagrilintide (amylin analog) + semaglutide. NDA submitted december 2025. the REDEFINE 1 trial showed 20.4% weight loss at 68 weeks vs 14.9% for semaglutide alone [9]. PDUFA date expected ~october 2026.
survodutide
Boehringer Ingelheim's dual glucagon/GLP-1 agonist targeting MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis. received fda breakthrough therapy designation september 2024. phase 2 showed MASH improvement in 62% of patients on the highest dose [10].
the compounding reclassification
in late 2023, the fda moved 19 widely-used peptides to category 2, effectively banning compounding pharmacies from preparing them. this included BPC-157, thymosin alpha-1, TB-500, CJC-1295, ipamorelin, selank, semax, GHK-Cu, KPV, MOTS-c, and others.
in february 2026, HHS secretary RFK Jr. announced that approximately 14 of these 19 peptides would be reclassified back to category 1, restoring legal compounding access with a valid prescription.
what category 1 means: compounding pharmacies can legally prepare these peptides for individual patients with a physician's prescription. it provides a legal pathway for access.
what category 1 does not mean: fda approval. none of these peptides have completed phase 3 clinical trials for their commonly promoted uses. there is no guarantee of efficacy for the conditions people use them for. the clinical evidence for most compounding peptides is limited to cell studies, animal models, and small uncontrolled human studies.
6 misconceptions that trip people up
- "research use only" means it's safe for humans -- false. RUO is a legal disclaimer for laboratory reagents, not a quality standard for human use. it explicitly means the product has not been validated for diagnostic or therapeutic application.
- personal use of unapproved peptides is legal -- false. buying peptides online outside a regulated pharmacy dispensing pathway has no legal protection. the fda considers unapproved peptides sold for human use to be misbranded and adulterated drugs.
- off-label prescribing covers research peptides -- false. off-label use applies only to drugs already fda-approved for at least one condition. BPC-157 has zero approvals, so off-label doesn't apply. a physician cannot legally prescribe an unapproved substance off-label.
- category 1 reclassification equals fda approval -- false. category 1 restores compounding access. it says nothing about efficacy. the reclassification is a regulatory pathway decision, not a clinical endorsement.
- all peptides carry the same risk profile -- false. semaglutide has completed trials in tens of thousands of patients. BPC-157's human safety data comes from a handful of small studies. equating their risk profiles is a category error.
- compounded peptides are identical to fda-approved versions -- false. compounded preparations have no guarantee of identity, purity, potency, or safety compared to manufactured pharmaceuticals. quality depends entirely on the compounding pharmacy's standards and oversight.
frequently asked questions
over 80 peptide-based drugs have received fda approval as of 2026. these range from widely prescribed medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) to niche treatments like afamelanotide (Scenesse) for erythropoietic protoporphyria. the number continues to grow as peptide drug development accelerates.
yes. semaglutide is a 31-amino-acid peptide analog of human GLP-1 (glucagon-like peptide-1). it has 94% sequence homology with native GLP-1 but includes modifications that extend its half-life from minutes to approximately one week. it is the most commercially successful peptide drug in history.
it depends on your jurisdiction and the source. as of early 2026, BPC-157 is expected to be reclassified to category 1 under the fda's bulk drug substance framework, which would restore legal compounding access with a valid prescription from a licensed physician. this does not make BPC-157 an fda-approved drug. purchasing from unregulated online vendors outside the pharmacy system has no legal protection.
fda approval requires clinical trials demonstrating safety and efficacy for a specific indication. this is the pathway for drugs, including peptide therapeutics. fda clearance (510(k)) applies to medical devices that demonstrate substantial equivalence to an already-marketed device. peptide drugs go through the approval pathway, not clearance. the distinction matters because "fda-cleared" does not mean a product has undergone clinical trials.
compounded peptides from licensed 503A or 503B pharmacies follow USP standards for sterility, potency, and purity. however, compounded preparations do not undergo the same rigorous testing as fda-approved manufactured drugs. quality can vary between pharmacies. the safest approach is to use a 503B outsourcing facility that voluntarily registers with the fda and undergoes regular inspections.
tirzepatide currently holds the highest weight loss figure in head-to-head trials: 20.2% mean body weight loss versus semaglutide's 13.7% in the SURMOUNT-5 trial at 72 weeks. however, retatrutide's phase 3 TRIUMPH-4 data showed 28.7% mean weight loss at 68 weeks, though this was not a head-to-head comparison. both tirzepatide and semaglutide are fda-approved; retatrutide is still in clinical trials.
retatrutide is in phase 3 clinical trials with Eli Lilly. the TRIUMPH-4 results showed 28.7% mean weight loss at 68 weeks, the highest phase 3 figure ever recorded for an obesity drug. seven additional phase 3 readouts are expected in 2026. the earliest realistic fda approval window is 2027-2028, assuming positive results and a standard review timeline.
references
- Muttenthaler M, King GF, Adams DJ, Alewood PF. "Trends in peptide drug discovery." Nature Reviews Drug Discovery. 2021;20:309-325.
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002.
- Novo Nordisk. "OASIS 4: Oral Semaglutide 25 mg Phase 3 Results." 2025.
- FDA. "FDA Approves Zepbound for Obstructive Sleep Apnea." December 2024.
- Aronne LJ, Horn DB, le Roux CW, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." N Engl J Med. 2025;393(1):26-36.
- Buckley ST, et al. "Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist." Sci Transl Med. 2018;10(467):eaar7047.
- Uchitel OD, et al. "Selank: peptidergic regulation of neuropeptide expression." Bulletin of Experimental Biology and Medicine. 2016;162(2):215-218.
- Jastreboff AM, Kaplan LM, Frias JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity -- A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526.
- Novo Nordisk. "REDEFINE 1 Phase 3 Trial Results: CagriSema." 2025.
- Lau DCW, Erichsen L, Francisco-Lahana E, et al. "A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis." N Engl J Med. 2024.
go deeper on the peptides that matter
our mastery courses cover mechanism of action, clinical trial data, dosing protocols, and safety profiles for individual peptides. go beyond the headlines.